Literature DB >> 27663736

Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant.

Rongsheng E Wang1, Ying Wang2, Yuhan Zhang2, Chase Gabrelow2, Yong Zhang2, Victor Chi2, Qiangwei Fu2, Xiaozhou Luo3, Danling Wang2, Sean Joseph2, Kristen Johnson2, Arnab K Chatterjee2, Timothy M Wright2, Vân T B Nguyen-Tran2, John Teijaro4, Argyrios N Theofilopoulos4, Peter G Schultz5, Feng Wang6.   

Abstract

A variable region fusion strategy was used to generate an immunosuppressive antibody based on a novel "stalk-knob" structural motif in the ultralong complementary-determining region (CDR) of a bovine antibody. The potent Kv1.3 channel inhibitory peptides Moka1-toxin and Vm24-toxin were grafted into different CDRs of the humanized antibodies BVK and Synagis (Syn) using both β-sheet and coiled-coil linkers. Structure-activity relationship efforts led to generation of the fusion protein Syn-Vm24-CDR3L, which demonstrated excellent selectivity and potency against effector human memory T cells (subnanomolar to picomolar EC50 values). This fusion antibody also had significantly improved plasma half-life and serum stability in rodents compared with the parent Vm24 peptide. Finally, this fusion protein showed potent in vivo efficacy in the delayed type hypersensitivity in rats. These results illustrate the utility of antibody CDR fusions as a general and effective strategy to generate long-acting functional antibodies, and may lead to a selective immunosuppressive antibody for the treatment of autoimmune diseases.

Entities:  

Keywords:  Kv1.3; antibody; autoimmune; immunosuppressive; protein engineering

Mesh:

Substances:

Year:  2016        PMID: 27663736      PMCID: PMC5068325          DOI: 10.1073/pnas.1612803113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells.

Authors:  Zoltan Varga; Georgina Gurrola-Briones; Ferenc Papp; Ricardo C Rodríguez de la Vega; Gustavo Pedraza-Alva; Rajeev B Tajhya; Rezso Gaspar; Luis Cardenas; Yvonne Rosenstein; Christine Beeton; Lourival D Possani; Gyorgy Panyi
Journal:  Mol Pharmacol       Date:  2012-05-23       Impact factor: 4.436

2.  A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library.

Authors:  Zoltan Takacs; Megan Toups; Astrid Kollewe; Erik Johnson; Luis G Cuello; Gregory Driessens; Matthew Biancalana; Akiko Koide; Cristiano G Ponte; Eduardo Perozo; Thomas F Gajewski; Guilherme Suarez-Kurtz; Shohei Koide; Steve A N Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

Review 3.  Cyclosporine: the base for immunosuppressive therapy--present and future.

Authors:  B D Kahan
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

4.  Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.

Authors:  Alexander Schmitz; Ananthakrishnan Sankaranarayanan; Philippe Azam; Kristina Schmidt-Lassen; Daniel Homerick; Wolfram Hänsel; Heike Wulff
Journal:  Mol Pharmacol       Date:  2005-08-11       Impact factor: 4.436

5.  Rational design of a humanized glucagon-like peptide-1 receptor agonist antibody.

Authors:  Yong Zhang; Huafei Zou; Ying Wang; Dawna Caballero; Jose Gonzalez; Elizabeth Chao; Gus Welzel; Weijun Shen; Danling Wang; Peter G Schultz; Feng Wang
Journal:  Angew Chem Int Ed Engl       Date:  2014-12-29       Impact factor: 15.336

6.  Structure, function, and chemical synthesis of Vaejovis mexicanus peptide 24: a novel potent blocker of Kv1.3 potassium channels of human T lymphocytes.

Authors:  Georgina B Gurrola; Rogelio A Hernández-López; Ricardo C Rodríguez de la Vega; Zoltan Varga; Cesar V F Batista; Saida P Salas-Castillo; Gyorgy Panyi; Federico del Río-Portilla; Lourival D Possani
Journal:  Biochemistry       Date:  2012-05-07       Impact factor: 3.162

7.  Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.

Authors:  Christine Beeton; Heike Wulff; Nathan E Standifer; Philippe Azam; Katherine M Mullen; Michael W Pennington; Aaron Kolski-Andreaco; Eric Wei; Alexandra Grino; Debra R Counts; Ping H Wang; Christine J LeeHealey; Brian S Andrews; Ananthakrishnan Sankaranarayanan; Daniel Homerick; Werner W Roeck; Jamshid Tehranzadeh; Kimber L Stanhope; Pavel Zimin; Peter J Havel; Stephen Griffey; Hans-Guenther Knaus; Gerald T Nepom; George A Gutman; Peter A Calabresi; K George Chandy
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

8.  Rational design of antibody protease inhibitors.

Authors:  Tao Liu; Guangsen Fu; Xiaozhou Luo; Yan Liu; Ying Wang; Rongsheng E Wang; Peter G Schultz; Feng Wang
Journal:  J Am Chem Soc       Date:  2015-03-19       Impact factor: 15.419

9.  CD28nullCD4+ T cells--characterization of an effector memory T-cell population in patients with rheumatoid arthritis.

Authors:  A E R Fasth; D Cao; R van Vollenhoven; C Trollmo; V Malmström
Journal:  Scand J Immunol       Date:  2004 Jul-Aug       Impact factor: 3.487

10.  Glutamate levels and activity of the T cell voltage-gated potassium Kv1.3 channel in patients with systemic lupus erythematosus.

Authors:  C Poulopoulou; Z Papadopoulou-Daifoti; A Hatzimanolis; K Fragiadaki; A Polissidis; E Anderzanova; P Davaki; C G Katsiari; P P Sfikakis
Journal:  Arthritis Rheum       Date:  2008-05
View more
  11 in total

Review 1.  The impact of structural biology in medicine illustrated with four case studies.

Authors:  Tiancen Hu; Elizabeth R Sprague; Michelle Fodor; Travis Stams; Kirk L Clark; Sandra W Cowan-Jacob
Journal:  J Mol Med (Berl)       Date:  2017-07-01       Impact factor: 4.599

2.  A Switchable Site-Specific Antibody Conjugate.

Authors:  Zhigang Lyu; Lei Kang; Zakey Yusuf Buuh; Dawei Jiang; Jeffrey C McGuth; Juanjuan Du; Haley L Wissler; Weibo Cai; Rongsheng E Wang
Journal:  ACS Chem Biol       Date:  2018-02-28       Impact factor: 5.100

3.  A humanized antibody inhibitor for cathepsin L.

Authors:  Xiaojing Shi; Yong Zhang
Journal:  Protein Sci       Date:  2020-08-07       Impact factor: 6.725

Review 4.  The Kv1.3 K+ channel in the immune system and its "precision pharmacology" using peptide toxins.

Authors:  Zoltan Varga; Gabor Tajti; Gyorgy Panyi
Journal:  Biol Futur       Date:  2021-02-06

5.  Rational Design of a Humanized Antibody Inhibitor of Cathepsin B.

Authors:  Zhefu Dai; Qinqin Cheng; Yong Zhang
Journal:  Biochemistry       Date:  2020-03-31       Impact factor: 3.162

6.  A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3.

Authors:  Janna Bednenko; Rian Harriman; Lore Mariën; Hai M Nguyen; Alka Agrawal; Ashot Papoyan; Yelena Bisharyan; Joanna Cardarelli; Donna Cassidy-Hanley; Ted Clark; Darlene Pedersen; Yasmina Abdiche; William Harriman; Bas van der Woning; Hans de Haard; Ellen Collarini; Heike Wulff; Paul Colussi
Journal:  MAbs       Date:  2018-04-02       Impact factor: 5.857

7.  Eplerenone Reverses Cardiac Fibrosis via the Suppression of Tregs by Inhibition of Kv1.3 Channel.

Authors:  Pei-Pei Shao; Chang-Jiang Liu; Qi Xu; Bo Zhang; Shao-Hua Li; Yang Wu; Zhan Sun; Lu-Feng Cheng
Journal:  Front Physiol       Date:  2018-07-13       Impact factor: 4.566

8.  Animal protein toxins: origins and therapeutic applications.

Authors:  Na Chen; Siqi Xu; Yuhan Zhang; Feng Wang
Journal:  Biophys Rep       Date:  2018-10-11

Review 9.  Ion channels as therapeutic antibody targets.

Authors:  Catherine J Hutchings; Paul Colussi; Theodore G Clark
Journal:  MAbs       Date:  2018-12-10       Impact factor: 5.857

10.  Epitope-directed antibody selection by site-specific photocrosslinking.

Authors:  Longxin Chen; Chaoyang Zhu; Hui Guo; Runting Li; Limeng Zhang; Zhenzhen Xing; Yue Song; Zihan Zhang; Fuping Wang; Xiaofeng Liu; Yuhan Zhang; Runlin Z Ma; Feng Wang
Journal:  Sci Adv       Date:  2020-04-01       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.